|
|
Calliditas Therapeutics Ab (NASDAQ: CALT) |
|
|
|
| |
Calliditas Therapeutics Ab's Revenue per Employee
Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales
With a revenue increase of 49.74% in the forth quarter 2023, year on year to cumulative value of $129 million, Calliditas Therapeutics Ab's revenue per employee grew on a trailing twelve months basis to $ 1,520,479, this is below the company average. Within the Healthcare sector Employees of 27 other companies have achieved higher revenue per employee. While Calliditas Therapeutics Ab's total ranking has deteriorated compared to the previous quarter from 0 to 309. Calliditas Therapeutics Ab has 85 employees.
What is Sales per Employee Ratio?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| CALT Revenue per Employee |
(Dec 31 2023)
IV. Quarter |
0
III. Quarter |
0
II. Quarter |
0
I. Quarter |
(Dec 31 2022)
IV. Quarter |
| Y / Y Revenue Change |
49.74 % |
- |
- |
- |
- |
| Sales per Employee
(TTM) $ |
1,520,479 |
1,015,406 |
1,015,406 |
1,015,406 |
1,015,406 |
| CALT's Total
Ranking |
# 309 |
# 0 |
# 0 |
# 0 |
# 520 |
| Seq. Revenue Change |
- |
- |
- |
- |
- |
| Revenue per Employee Statistics |
| High |
Average |
Low |
| $ 2,154,011 |
$ 1,796,252 |
$ 1,438,492 |
| (Dec 31 2023) |
|
(Dec 31 2022) |
News about Calliditas Therapeutics Ab |
|
In a significant move to strengthen its financial position, Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) have recently announced the successful refinancing of its existing term loan. The company has secured a Euro 92 million senior secured facility with funds managed by Athyrium Capital Management, LP (Athyrium). This strategic collaboration aims to fuel the future growth prospects of Calliditas in the pharmaceutical industry.
Rising Productivity and Revenue Per Employee:
Calliditas Therapeutics has been experiencing exceptional growth in terms of revenue per employee. Over the trailing twelve months, the company s revenue per employee has reached an all-time high, reflecting the productivity and effectiveness of their workforce. This achievement underscores Calliditas commitment to driving efficiency and maximizing results.
|
Date modified: 2024-04-25T12:07:01+00:00
| Companies with similar Revenue per Employee for 12 months ending Dec 31 2023, within Healthcare Sector | Revenue per Employee | Revenue 12 months ending Dec 31 2023 | Number of Employees Dec 31 2023 | | Harmony Biosciences Holdings inc | 2,364,983.74 | $ 581.786 Million | 246 | | Alpine Immune Sciences Inc | 2,355,040.00 | $ 58.876 Million | 25 | | Intra cellular Therapies Inc | 2,298,861.39 | $ 464.370 Million | 202 | | Xeris Biopharma Holdings Inc | 2,276,583.33 | $ 163.914 Million | 72 | | Ardelyx Inc | 2,272,888.89 | $ 163.648 Million | 72 | | Hims and Hers Health Inc | 2,190,826.63 | $ 871.949 Million | 398 | | Assertio Holdings inc | 2,172,414.29 | $ 152.069 Million | 70 | | Semler Scientific Inc | 2,130,750.00 | $ 68.184 Million | 32 | | Mirum Pharmaceuticals Inc | 2,025,804.35 | $ 186.374 Million | 92 | | United Therapeutics Corporation | 1,992,722.60 | $ 2,327.500 Million | 1,168 | | Beam Therapeutics Inc | 1,987,942.11 | $ 377.709 Million | 190 | | Prestige Consumer Healthcare Inc | 1,986,842.11 | $ 1,132.500 Million | 570 | | The Beauty Health Company | 1,985,565.00 | $ 397.113 Million | 200 | | Biofrontera Inc | 1,939,150.00 | $ 116.349 Million | 60 | | American Shared Hospital Services | 1,849,454.55 | $ 20.344 Million | 11 | | Vertex Pharmaceuticals Inc | 1,827,629.63 | $ 9,869.200 Million | 5,400 | | Hutchmed china Limited | 1,794,430.41 | $ 837.999 Million | 467 | | Inspire Medical Systems inc | 1,768,337.11 | $ 624.223 Million | 353 | | Spero Therapeutics Inc | 1,759,000.00 | $ 103.781 Million | 59 | | Entrada Therapeutics Inc | 1,720,173.33 | $ 129.013 Million | 75 | | Biocryst Pharmaceuticals Inc | 1,682,294.42 | $ 331.412 Million | 197 | | Capricor Therapeutics inc | 1,678,537.73 | $ 25.178 Million | 15 | | Esperion Therapeutics inc | 1,661,914.29 | $ 116.334 Million | 70 | | Lantheus Holdings Inc | 1,553,408.87 | $ 1,295.543 Million | 834 | | Calliditas Therapeutics Ab | 1,520,478.68 | $ 129.241 Million | 85 | | Zomedica Corp | 1,519,875.00 | $ 24.318 Million | 16 | | Gilead Sciences Inc | 1,506,444.44 | $ 27,116.000 Million | 18,000 | | Privia Health Group Inc | 1,504,298.55 | $ 1,657.737 Million | 1,102 | | G1 Therapeutics Inc | 1,500,200.00 | $ 82.511 Million | 55 | | Paragon 28 inc | 1,496,076.39 | $ 215.435 Million | 144 |
|
